Decision Support Tool to Enhance Germline Genetic Testing for Patients With Prostate Cancer

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age18+
SponsorM.D. Anderson Cancer Center

About this trial

This clinical trial identifies factors associated with completing genetic testing, aids in the development of a decision support tool, and tests how well the decision support tool works to enhance germline genetic testing in patients with prostate cancer. Germline genetic testing is a guideline-recommended standard of care for many patients with prostate cancer. Completing genetic testing can enable the use of targeted therapies, offers access to novel clinical trials, provides valuable information, and can help identify at risk family members. The decision support tool may educate patients and assist in the decision to engage with germline genetic testing.

Eligibility criteria

Qualifiers

Diagnosed prostate cancer patients receiving care at Lyndon B. Johnson (LBJ) Hospital

Were recommended for germline genetic testing by their oncology provider

Can provide informed consent

Can communicate in English or Spanish

Disqualifiers

Prostate cancer patients receiving care at LBJ who are unable to participate due to a serious psychological or cognitive condition

Trial design

Treatments tested in this trial

  • Behavioral Intervention
  • Biospecimen Collection
  • Electronic Health Record Review
  • Genetic Counseling
  • Genetic Testing
  • Interview
  • Interview
  • Survey Administration

Treatment groups

108 Participants
are divided into 3 treatment groups

Locations

1
M D Anderson Cancer Center77030, HoustonTexas, United States

Sponsors and collaborators

M.D. Anderson Cancer Center

Lead sponsor